Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
A recently published article in the American Journal of Clinical Pathology about the submission of tumour blocks for NCTN trials is the result of work done by the Group Banking Committee of the US NCI which CCTG is a charter member.(Publication)
Thanks to all of the CCTG sites who participated, making Canada one of the top 10 accruing countries globally and responsible for a quarter of the North American patients enrolled on the trial. As of December 2019 the final international accruals were 518 patients (target: 500) with 29 enrolled patients from Canada.
Clinical Research Associate (CRA) Volunteers Needed for Endpoint & Disease Site Executive Committees!
The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Gastrointestinal and Genitourinary Disease Site Committee Executives as well as Supportive Care Committee.
The Commonwealth Neuroendocrine Tumour (CommNETs) Research Collaborative held their annual research workshop on December 7 & 8th 2019 in Tokyo Japan. Operating within the auspices of CCTG and AGITG (Australasian Gastro-Intestinal Trials Group) CommNETs provides a valuable forum for NET research collaboration among Canadian, Australian and New Zealand clinicians, researchers and patient representatives.
Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.
SC26 Emotion and Symptom-focused Engagement (EASE): A Randomized Controlled Trial for Individuals with Acute Leukemia has been centrally activated.
